Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NWLrU3loS2WubDDWbYFjcWyrdImgRZN{[Xl? MkXENE0xNjVizszN NWHKeHZ6OjRiaB?= NFnsV5Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWiyOVY3Ozd4OR?=
HepG2-HBV1.1 NX\HSol7SXCxcITvd4l{KEG|c3H5 MnvNNE0xNjVizszN NV[yU4ZwOjRiaB?= MYTpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NET1OnAzPTZ4M{e2PS=>
HepG2.2.15 NFjBU5FHfW6ldHnvckBCe3OjeR?= MlLHNE4yKM7:TR?= NF74e4czPCCq MWrwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M1ruPFI2PjZ|N{[5
HepG2-HBV1.1 M2TmcmZ2dmO2aX;uJGF{e2G7 NGnGdHAxNjFizszN MUiyOEBp MlfWdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NXO3R2VkOjV4NkO3Olk>
HepG2-HBV1.1 NVzFbXRkTnWwY4Tpc44hSXO|YYm= NUnMXmg2OC5zIN88US=> MW[0PEBp NX\uNXFmeHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW| NHjqV|YzPTZ4M{e2PS=>
HepG2-HBV1.1 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KwPFAvOSEQvF2= Mmm2NU02KGR? MV3pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 NX;tZ2ZkOjV4NkO3Olk>
HepG2-HBV1.1 NXTNPVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPhNE4yKM7:TR?= Ml7qNU02KGR? NFvS[XNqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NWPVVJhwOjV4NkO3Olk>
HepG2-HBV1.1 NWfyVFZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX4XWxEOC5zIN88US=> NHzxOGgyOi15MjDo NWTWdpd1cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm NG\nWIQzPTZ4M{e2PS=>
HepG2-HBV1.1 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jj[|AvOSEQvF2= M2XW[VEzNTd{IHi= NYjve5ZWcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm NF[zeGgzPTZ4M{e2PS=>
Raji NV;5cnU4TnWwY4Tpc44hSXO|YYm= NFTCWnUxNjYEoN88US=> MoP1O|IhcA>? NGrpblNi[m:uaYPo[ZMh[XW2b4DoZYd6yqB? NUDpbmFUOjV2NE[zO|c>
SK-MEL-28  MlzZSpVv[3Srb36gRZN{[Xl? MkDWN|Ahdk1? M1rrelYhcA>? NGLQXpZqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= MnrONlU{OTNyMUC=
H157 M3LrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4bGlEPTB;MT6wN{DDuSByLkC0JI1qfTKP NWHS[5dnOjV{NUe5NVE>
Jurkat MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLRNU0{KG6P NVrsdZU2PDkEoHi= NH;QPXlFVVOR M4HUNIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MlHENlUyPTZzNE[=
CEM M{HNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4U4MyNTNibl2= M1HBVFQ5yqCq M{XxUmROW09? MY\k[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NXr5SFI2OjVzNU[xOFY>
P12 NVe0cIpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrINU0{KG6P MljaOFjDqGh? MnPkSG1UVw>? NY\pc|dT\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NH;XUWczPTF3NkG0Oi=>
KB M4n6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHtfmNKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN M4[xOFI2ODV6NUK2
KBv200 (ABCB1) Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfoeYRmUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> M{nPV|I2ODV6NUK2
SUDHL6  MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHaNgKBkc7:TR?= M4myd|Q5Nzd{IHi= M{DSc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NFjOVHEzPDl4MU[wOC=>
SUDHL6  M1q3UmZ2dmO2aX;uJGF{e2G7 NWLSeHQzOeLCid88US=> NYDJS2YzPzJiaB?= MX;pcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C M3j5NlI1QTZzNkC0
HCT-116 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjsTmRIUTVyPUWgcm0> MX[yOFkzPzh3Nx?=
SKNBe2C NEnKVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i0dWlEPTB;M{KuPOKyPC5yIH7N M{HnOlI1QTJzOUKw
IGNR91 M1zxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfyeG5KSzVyPUK0MlPDuTFwNzDuUS=> MlLnNlQ6OjF7MkC=
SKNAS NFjpRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNdMxNE4zKG6P MVWyOFkzOTl{MB?=
LAN1 NGPBN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonUTWM2OD1{LkRCtVAvOiCwTR?= MXGyOFkzOTl{MB?=
SHSY5Y NVrYdXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTFeoFKSzVyPUiuNuKyOC54IH7N MXeyOFkzOTl{MB?=
A549-WT NHz2cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfWVWpkUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N M2nXflI1QDV6OEK3
A549-R MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fvU2lEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= MYeyOFg2QDh{Nx?=
MCF-7-WT NV3kd5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ps[GlEPTB;MUeuO|UzKMLzIECuNlE5KCCwTR?= NFTXSHgzPDh3OEiyOy=>
MCF-7-R M2ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnWfI9KSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?= NFnWcG8zPDh3OEiyOy=>
A549-R NFL4WYREgXSxdH;4bYNqfHliQYPzZZk> MUXJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? NHjubnkzPDh3OEiyOy=>
MCF-7-R MX7DfZRwfG:6aXPpeJkhSXO|YYm= NGPxOGVKSzVyPUWuOVM6KMLzIECuNVQ1KG6P MV6yOFg2QDh{Nx?=
SW620 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdwOECgxtEhOC5yODDuUS=> MUCyOFczPjd|OR?=
SW620/AD300 M2nCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zO[mlEPTB;OUC5MlYxKMLzIEiuPVEhdk1? NEfMNXozPDd{NkezPS=>
HEK293/pcDNA3.1 M{XlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Gd2FDUUN3ME2xMlQ2KMLzIECuNlAhdk1? M1j1OFI1PzJ4N{O5
HEK293/ABCC1 NGDW[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF7LkK5JOKyKDJwMEigcm0> M{j4b|I1PzJ4N{O5
TCC M1zMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDONlQhcA>? NWHTe3VVUUN3ME23NEBvVQ>? MXKyOFcyPjl2NB?=
TCC Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\iVIVtPDhiaB?= NYrTUlgxUUN3ME21NEBvVQ>? NXz0UIpbOjR5MU[5OFQ>
HepG2/ADM NV7yfnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? NGrqNJozPDdyNEW1Oi=>
HepG2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HlNmlEPTB;MD6wNVE2yrFyLkCwNVch|ryP NFnJUZMzPDdyNEW1Oi=>
MCF-7/ADR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? NWfXVnBIOjR5MES1OVY>
MCF-7 M1np[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7yTWM2OD1yLkCxOVnDuTBwMEC2NkDPxE1? M1rI[FI1PzB2NUW2
A-172  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHXNE4yyqEQvF2= NXTqN3FQOjRxN{KgbC=> MYjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M3TI[VI1PTNyMkO1
U-251MG MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHH[3o1OC5zwrFOwG0> NXrObW92OjRxN{KgbC=> NVPGUYJscW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MXmyOFU{ODJ|NR?=
DLD-1 M2PBfmZ2dmO2aX;uJGF{e2G7 M{jMSFExOCCwTR?= MUS0PEBp MkP2dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NXHXelJWOjR2MEO0OVM>
CCD18Co NGfo[ZlHfW6ldHnvckBCe3OjeR?= Mlq2NVAxKG6P MXW0PEBp NWXVZWFxeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NEPXc5IzPDRyM{S1Ny=>
DLD-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VT|AuOTByMDDuUS=> NGLTNlE1QCCq NXPEXpVCcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M3nIV|I1PDB|NEWz
CCD18Co NX3YZ3piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPrdoZJOC1zMECwJI5O MkDROFghcA>? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVPIVIN7OjR2MEO0OVM>
HepG2 M{nSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fIclI1KGh? MWfJR|UxRTV{LkZihKnPxE1? NEjsV5czPDN2MU[4PC=>
HEK293/pcDNA3.1 NVXH[mJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? NGTafIszPDJ6NEe4Ny=>
HEK293/MRP1 NGrwepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7sTWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? MUKyOFI5PDd6Mx?=
Ramos NXnYWYU4SXCxcITvd4l{KEG|c3H5 MX2y5qCK|ryP NHTMXJg1QCCq NUSxTVU5cW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| NUPxO3ZROjR{NU[0PVE>
NCI-H1299/pcDNA3 M4T4WGNmdGxiVnnhZoltcXS7IFHzd4F6 MknxNE0zOCCwTR?= M4DNVVk3KGh? MWfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnXLNlQyPzdyMUK=
H1299/ICAM-3 NI\wdldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2TFV|AuOjBibl2= M4PTeFk3KGh? M1\PcIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NW\ENY1rOjRzN{ewNVI>
NCI-H1299/pcDNA3 MmrzSpVv[3Srb36gRZN{[Xl? MnjoNU82NzFyL{KwxsBvVQ>? NWHSfWRyQTZiaB?= M1y0ZYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> NGrZfWEzPDF5N{CxNi=>
H1299/ICAM-3 NHLyO4NHfW6ldHnvckBCe3OjeR?= Mk\xNU82NzFyL{KwxsBvVQ>? M1zkWFk3KGh? NEjTUZZqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR NWjjUJBDOjRzN{ewNVI>
W1 M2jLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMECzNkDPxE1? MViyOFE1ODF5Nh?=
W1VR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jodmlEPTB;MD6wOVYh|ryP Ml2yNlQyPDBzN{[=
K562 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? M4WwPVI1OTN3OUO3
K562/ADR M1LEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSyTWM2OD1|LkK2NUDDuSByLkSxNkDPxE1? M4LmfFI1OTN3OUO3
K562 NWf3dI5YSXCxcITvd4l{KEG|c3H5 M2nZNlAvOyEQvF2= NUPJV|ZiOjRiaB?= NHXtO29qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M4nnSlI1OTN3OUO3
K562/ADR NF7yN2dCeG:ydH;zbZMhSXO|YYm= NHzaTok{KM7:TR?= NUKxPYRXOjRiaB?= NEfFWI5qdmS3Y3XzJIFxd3C2b4Ppdy=> MXKyOFE{PTl|Nx?=
A549 NELNe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6OG9ZUUN3ME2wMlExKMLzIECuNFMh|ryP NEPnfnkzOzl5MUC3OS=>
K562 M1fXVmNmdGxiVnnhZoltcXS7IFHzd4F6 M{jkcFMvPzYkgKO2NOKhdk1? M4n3WFczyqCqwrC= NXL1fnpMcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NUf5N2U1OjN6N{eyNlM>
lucena M37aUmNmdGxiVnnhZoltcXS7IFHzd4F6 NGTL[JU{Njd34pETOlDDqG6P NWe0dpJ5PzMEoHlCpC=> MnrNco8h\W[oZXP0 NED6ZmszOzh5N{KyNy=>
FEPS MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFi1N4M{Njd34pETOlDDqG6P NIrVWVk4OsLiaNMg NHTYbY9vdyCnZn\lZ5Q> MYSyN|g4PzJ{Mx?=
A2780 NELHUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCwZ49{UUN3ME2zMlUhdU1? NVLxVlMyOjN6MkmyNFM>
ACHN NWDUT|ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrNd4lKSzVyPECuNUBuVQ>? NVHUcWdVOjN6MkmyNFM>
U-937 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jNcmlEPTB:M{Sgcm0> NInJemEzOzh{OUKwNy=>
Jurkat NHvrdpdCeG:ydH;zbZMhSXO|YYm= MXq1xsDPxGdxbX|CpC=> MofmNlQhcA>? MlfWbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NWHyPHJqOjN6MUC0NFk>
Jurkat NGnRbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DCfVXDqM7:Zz;tcOKh M3zT[|I1KGh? MXXhdpJme3RiSoXyb4F1KGOnbHzzJIlvKEd{L12gdIhie2V? NY\LO3pKOjN6MUC0NFk>
Hep-2 M3jufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jWOWlEPTB;MD6wOOKyOC5yMTFOwG0> MlXWNlM4QDB2MkS=
Hep-2/v NWr6boljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSwTWM2OD1zLklCtVAvOjBizszN NIfKcnozOzd6MESyOC=>
SGC-7901 NEX5fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnpNE0yOCEQvHevcYw> NGfiWo8zPC92OD:3NkBp NIrNVVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NUL5OFBXOjN5NEO1O|I>
SGC-7901/VCR M1nrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMVExKM7:Zz;tcC=> MmDENlQwPDhxN{KgbC=> M4PXR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXH4[5hYOjN5NEO1O|I>
SGC-7901 NIPNUXBCeG:ydH;zbZMhSXO|YYm= NIDEdWdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M{mzT|I{PzR|NUey
SGC-7901/VCR NEKz[IhCeG:ydH;zbZMhSXO|YYm= MUjpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NGT2e4IzOzd2M{W3Ni=>
KB-3-1 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn23TWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? NGD1R3UzOzZ5M{S0OS=>
KB-C2 M3zVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTjXIZKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN Mof2NlM3PzN2NEW=
KB-3-1 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HTbmlEPTB;MT6yOkDDuSByLkCyO{DPxE1? NHWzfpUzOzZ5M{S0OS=>
KB-V1 M2fNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr3TWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1? NUPJfWNWOjN4N{O0OFU>
HEK293/pcDNA3.1 NVzmR5k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ2LkGgxtEhOC5{MESg{txO MWSyN|Y4OzR2NR?=
HEK293/ABCB1 NWT5dnZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPvfIxMUUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> MYCyN|Y4OzR2NR?=
A549/EGFP  Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHPNE4xOS1zMECwJO69VQ>? MmjaTWM2OD16Nj63JOKyKDJ7LkGg{txO Mnf4NlM3OzR{OEK=
A549/Slug NXn5T3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fxUlAvODFvMUCwNEDPxE1? NGDkRoZKSzVyPUmuO{DDuSB|LkGg{txO MWOyN|Y{PDJ6Mh?=
JFCR39  NInXOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLlNUDDvU1? NWXQdoZWOjRiaB?= MmnmSG1UVw>? NET2Sodu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| MWGyN|U6QDJ5Nh?=
A549 NVrJNolJTnWwY4Tpc44hSXO|YYm= MoDCNVAxKG6P M{D6NFE3KGh? MUnEUXNQ NILmPFFt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| NYf6PXV6OjN3OUiyO|Y>
SGC7901 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:5TmVKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t MlXWNlM2PjR2OEK=
SGC7901/LV-NC NHPM[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTDRnYyUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? MmjtNlM2PjR2OEK=
SGC7901/LV-SGO1 NFjmW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULRO5c{UUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>? NXzuVGJuOjN3NkS0PFI>
SGC7901/VCR MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnX[IlKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? MlLuNlM2PjR2OEK=
SGC7901/VCR-NC NVnQRmFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLsTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> MnXzNlM2PjR2OEK=
SGC7901/VCR-si-SGO1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXY[WtuUUN3ME22MlE56oDLwsJihKkyNjB|IN88[{9udA>? NXvjZolIOjN3NkS0PFI>
SGC7901/ADR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPwUXdjUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? M3SzcVI{PTZ2NEiy
SGC7901/ADR-NC NFP0Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV76SmkxUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? NH3KPVUzOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 NXXOWVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLxTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> MlT2NlM2PjR2OEK=
SH-SY5Y  NXvhUnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq4[Is2OC5yMEGtNVAh|ryP MVqyOEBp NYfGT2NQUUN3ME2wMlEyO8LzMD6wNVIh|ryP NWC0W4VzOjNzMkmwOlU>
SH-SY5Y  Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[wMlAxOS1zMDFOwG0> MlvvOFghcA>? NF3ON5hKSzVyPUCuNFc5yrFyLkCwPUDPxE1? M{XCV|I{OTJ7ME[1
SH-SY5Y  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjMZ2kxNjByMT2xNEDPxE1? NUm3SWUzPzJiaB?= NVzud5UyUUN3ME2wMlA2OcLzMD6wNFgh|ryP MUKyN|EzQTB4NR?=
SH-SY5Y MW\BdI9xfG:|aYOgRZN{[Xl? M17iUlAvOSEQvF2= NWXUfpZWOC1{NDDo M1fmPYlv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl NX3SbHBGOjNzMkmwOlU>
SH-SY5Y MmjyRZBweHSxc3nzJGF{e2G7 M2fFcVAvOSEQvF2= M2HQVFAuOjRiaB?= MU\pcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? MXWyN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami March 2019 Phase 1
NCT03710772 Not yet recruiting CD20 Positive|Mantle Cell Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) January 31 2019 Phase 2
NCT03613428 Not yet recruiting Acute T Cell Leukemia Sichuan University December 1 2018 Phase 1|Phase 2
NCT03742258 Not yet recruiting Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Northwestern University|National Cancer Institute (NCI) December 29 2018 Phase 1
NCT03704714 Not yet recruiting Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI) November 8 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID